|
US2021115493A1
|
|
Methods for determining a drug dosing regimen
|
|
US2021113548A1
|
|
Methods for determining a drug dosing regimen
|
|
WO2020236502A1
|
|
Combination therapies for cancer treatment
|
|
WO2020242773A1
|
|
Methods of promoting differentiation of myeloid-derived suppressor cells using inhibitors of dihydroorotate dehydrogenase
|
|
WO2020219423A1
|
|
Combination therapies including inhibitors of dihydroorotate dehydrogenase
|
|
WO2020185805A1
|
|
Immune modulation by brequinar
|
|
WO2020163412A1
|
|
Compositions and methods for inhibiting inosine monophosphate dehydrogenase
|
|
WO2020163411A1
|
|
Compositions and methods for inhibiting inosine monophosphate dehydrogenase
|
|
WO2020123246A1
|
|
Therapeutic methods using multiple agents that achieve the same phenotypic response
|
|
WO2020123241A1
|
|
Multiphasic dosing regimens for treating cancer
|
|
EP3773579A1
|
|
Compositions and methods for inhibiting dihydroorotate dehydrogenase
|
|
WO2019191030A1
|
|
Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
|
|
US2019290635A1
|
|
Methods of treating brain cancer using agents that alter activity of a metabolic pathway
|
|
US2019290892A1
|
|
Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
|
|
US2019290634A1
|
|
Compositions and methods for inhibiting dihydroorotate dehydrogenase
|
